RICHMOND, Calif., Jan. 13, 2021 (Globe NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an sector chief in exoskeleton know-how for healthcare and industrial use, right now introduced preliminary leading line monetary outcomes for the fourth quarter and fiscal calendar year ended December 31, 2020.
Whole profits for the fourth quarter of 2020 is an estimated $2.3 million, in comparison to complete income of $3.7 million in the fourth quarter of 2019. Overall revenue for fiscal 12 months 2020 is believed to be roughly $8.9 million, in contrast to $13.9 million in 2019.
Money at December 31, 2020 was $12.9 million, compared to $10.9 million at December 31, 2019.
“Our believed fourth quarter 2020 revenue mirrored stable effectiveness as we executed on crucial initiatives while navigating by COVID-relevant industry problems,” commented Jack Peurach, President and Main Executive Officer of Ekso Bionics. “During the quarter, we ongoing to get traction with our network operator tactic in the medical organization. We imagine that our new subscription design, which decreases capital constraints, will aid additional strategic promotions and additional develop our put in base in 2021. We are also happy that our most up-to-date industrial innovation, EVO™, produced strong buyer excitement and strong first adoption tendencies following its August 2020 launch. Looking forward, we keep on being assured that as the COVID situation enhances, our escalating pipeline of alternatives will create bigger momentum supported by our persuasive benefit propositions in equally the health care and industrial fronts.”
The predicted final results reviewed in this press release are centered on management’s preliminary, unaudited examination of monetary benefits for the period of time and year ended December 31, 2020. As of the day of this press launch, the Corporation has not accomplished its economical statement reporting procedure for the period and 12 months ended December 31, 2020, and the Company’s independent registered accounting firm has not audited the preliminary money info mentioned in this press launch. For the duration of the class of the Company’s quarter-finish closing techniques and evaluate method, the Business may possibly recognize things that would demand it to make adjustments, which may well be content to the facts introduced above. As a result, the estimates previously mentioned represent forward-looking info and are matter to dangers and uncertainties, together with doable changes to preliminary functioning results. The Organization expects to report complete fourth quarter and total 12 months 2020 economical effects throughout the previous week of February 2021.
About Ekso Bionics®
Ekso Bionics® is a foremost developer of exoskeleton remedies that amplify human likely by supporting or boosting energy, stamina and mobility across health care and industrial purposes. Started in 2005, the Enterprise proceeds to develop on its market-top experience to style and design some of the most cutting-edge, revolutionary wearable robots available on the current market. Ekso Bionics is the only exoskeleton enterprise to offer you technologies that range from encouraging those people with paralysis to stand up and wander, to boosting human capabilities on work web sites throughout the globe. The Business is headquartered in the San Francisco Bay Region and is outlined on the Nasdaq Cash Market beneath the symbol “EKSO.” For more facts, stop by: www.eksobionics.com or observe @EksoBionics on Twitter.
Any statements contained in this press launch that do not explain historic points may perhaps constitute ahead-looking statements. Forward-searching statements may possibly incorporate, without limitation, statements regarding (i) the strategies and targets of administration for upcoming functions, together with plans or goals relating to the layout, advancement and commercialization of human exoskeletons, strategies or method relating to the promoting and adoption and acceptance of the Company’s products and likely for adoption of the Company’s products by the market place, (ii) estimates or projection of economical effects, economic problem, capital expenses, funds structure or other economic merchandise, (iii) the Company’s long run fiscal performance and (iv) the assumptions underlying or relating to any assertion explained in details (i), (ii) or (iii) higher than. These types of forward-seeking statements are not intended to forecast or guarantee genuine outcomes, effectiveness, activities or conditions and may perhaps not be recognized since they are based upon the Company’s existing projections, programs, objectives, beliefs, expectations, estimates and assumptions and are matter to a range of risks and uncertainties and other influences, several of which the Corporation has no manage about. Real benefits and the timing of particular situations and conditions may possibly differ materially from those people described by the ahead-wanting statements as a end result of these dangers and uncertainties. Variables that may affect or contribute to the inaccuracy of the ahead-wanting statements or bring about precise final results to differ materially from expected or sought after effects may well include things like, without the need of limitation, improvements ensuing from the Company’s finalization of its monetary statements for and as of the period of time and 12 months finished December 31, 2020, data or new changes in information or conditions that might manifest prior to the submitting of the Company’s Once-a-year Report on Kind 10-K for the 12 months ended December 31, 2020 that are required to be provided in these annual report, the Company’s incapacity to acquire sufficient financing to fund the Company’s functions and needed to acquire or increase our technology, the considerable size of time and means linked with the improvement of the Company’s items, the Company’s failure to achieve broad sector acceptance of the Company’s merchandise, the failure of our profits and marketing organization or companions to market our goods successfully, adverse success in future medical scientific studies of the Company’s health-related device solutions, the failure to attain or retain patent defense for the Company’s technological innovation, failure to attain or retain regulatory acceptance to current market the Company’s professional medical devices, lack of solution diversification, present or improved opposition, the Company’s failure to carry out the Company’s business strategies or tactics and the influence of the COVID-19 pandemic. These and other variables are determined and described in a lot more depth in the Company’s filings with the SEC. To understand far more about Ekso Bionics please go to us at www.eksobionics.com or refer to our Twitter page at @EksoBionics. The Enterprise does not undertake to update these forward-searching statements.